Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 8:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 1,750 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Depression Severe Clear all
Recruiting Phase 2 Interventional

A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression

NCT07610473
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
DT-101, Placebo
Drug
Lead sponsor
Draig Therapeutics Ltd
Industry
Eligibility
18 Years to 75 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
23
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Bellflower, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 18, 2026, 8:48 AM EDT
Completed Phase 3 Interventional Results available

The Objective of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone

NCT03739203
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cariprazine, Placebo, Antidepressant Therapy (ADT)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
58
States / cities
Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 18, 2026, 8:48 AM EDT
Completed No phase listed Observational

Pilot Study: Establishing Glutamatergic Changes in Rapid Antidepressant Effects of Sleep Deprivation

NCT05893173
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Sleep Deprivation
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 85 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Oct 18, 2026, 8:48 AM EDT
Suspended No phase listed Observational

An Examination of the Performance of QbMobile in Differential Diagnosis Associated With ADHD Symptoms

NCT07329673
View directory record Official record
Conditions
Bi-Polar Disorder, Autism Spectrum Disorder (ASD), Major Depression Disorders, Separation Anxiety Disorder, Social Anxiety Disorder, Generalized Anxiety Disorder (GAD)
Interventions
Digital software application for cognitive performance and activity measurement (QbMobile, investigational device)
Device
Lead sponsor
Qbtech AB
Industry
Eligibility
6 Years to 60 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 18, 2026, 8:48 AM EDT
Terminated Not applicable Interventional Results available

rTMS for Depressed Teens: A Sham-Controlled Trial, Part 1

NCT01804270
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Repetitive transcranial magnetic stimulation (rTMS)
Device
Lead sponsor
Paul E. Croarkin
Other
Eligibility
12 Years to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Rochester, Minnesota • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Oct 18, 2026, 8:48 AM EDT
Not listed Not applicable Interventional

Evaluation of Programs of Coordinated Care and Disease Management

NCT00627029
View directory record Official record
Conditions
Congestive Heart Failure, Diabetes, Coronary Artery Disease, Chronic Obstructive Pulmonary Disease, Cancer, Cerebrovascular Disease, Alzheimer's Disease, Psychotic Disorder, Major Depression
Interventions
Care Coordination
Behavioral
Lead sponsor
Mathematica Policy Research, Inc.
Other
Eligibility
Not listed
Enrollment
18,277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2016
U.S. locations
15
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Sunrise, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2015 · Synced Oct 18, 2026, 8:48 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)

NCT06524830
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
VLS-01-203 BU, VLS-01-BU Placebo
Drug
Lead sponsor
atai Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
34
States / cities
Tucson, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 18, 2026, 8:48 AM EDT
Not yet recruiting Not applicable Interventional

Early Brainwave Biomarkers for Personalized Neuromodulation in Treatment-resistant Depression

NCT07528157
View directory record Official record
Conditions
Major Depressive Disorder, Treatment Resistant Depression
Interventions
Personalized iTBS, Non-Personalized iTBS, Sham iTBS
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 18, 2026, 8:48 AM EDT
Recruiting Not applicable Interventional

Investigating the Neural Mechanisms of Repetitive Brain Stimulation With Invasive and Noninvasive Electrophysiology in Humans

NCT05996900
View directory record Official record
Conditions
Major Depressive Disorder, Epilepsy
Interventions
Intracranial electrodes, TMS
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 18, 2026, 8:48 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Transcendental Meditation Intervention to Reduce Burnout and Enhance Resilience Among NewYork-Presbyterian Hospital and Weill Cornell Medicine Employees and Residents

NCT07868783
View directory record Official record
Conditions
Anxiety, Depression - Major Depressive Disorder, Burnout, Insomnia, Resilience, Feasibility, Acceptability
Interventions
Transcendental Meditation
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 18, 2026, 8:48 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Child And Adolescent Outpatients With Major Depressive Disorder

NCT00619619
View directory record Official record
Conditions
Depression, Major Depressive Disorder
Interventions
Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
7 Years to 17 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
9
States / cities
Little Rock, Arkansas • North Miami, Florida • Terre Haute, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2011 · Synced Oct 18, 2026, 8:48 AM EDT
Terminated Phase 3 Interventional Results available

Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD

NCT06011577
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
REL-1017, Placebo
Drug
Lead sponsor
Levomecor Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
36
States / cities
Dothan, Alabama • Homewood, Alabama • Anaheim, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 18, 2026, 8:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Using Electrophysiology to Index Non-invasive Brain Stimulation Effects on Reward System Functioning in Depression

NCT05194098
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
TMS: single session intermittent theta burst stimulation (iTBS) to dorsomedial prefrontal target in individuals with major depressive disorder, via MagVenture MagPro R30 device / Cool-DB80 A/P coil, SHAM (inactive) TMS stimulation
Device
Lead sponsor
San Francisco Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 18, 2026, 8:48 AM EDT
Terminated Not applicable Interventional Results available

Tapering Off Antidepressants

NCT02661828
View directory record Official record
Conditions
Major Depressive Disorder, Anxiety Disorder, Obsessive Compulsive Disorder, Post-Traumatic Stress Disorder
Interventions
Two-Week Antidepressant Taper Regimen, One-Week Antidepressant Taper Regimen
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Oct 18, 2026, 8:48 AM EDT
Completed Not applicable Interventional

Multifaceted Depression and Cardiovascular Program

NCT02069912
View directory record Official record
Conditions
Depression, Depressive Disorder, Behavioral Symptoms, Mood Disorders
Interventions
Collaborative depression care management
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 18, 2026, 8:48 AM EDT
Completed Phase 4 Interventional

Comparing the Effects of Four Types of Electroconvulsive Therapy on Mood and Thinking in People With Depression

NCT00487500
View directory record Official record
Conditions
Depression
Interventions
Electroconvulsive Therapy (ECT)
Device
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 90 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 18, 2014 · Synced Oct 18, 2026, 8:48 AM EDT
Completed Not applicable Interventional Results available

Bridge: Proactive Psychiatry Consultation and Case Management for Patients With Cancer

NCT03360695
View directory record Official record
Conditions
Cancer, Severe Major Depression, Schizophrenia, Bipolar Disorder, Lung Cancer, Breast Cancer, Head and Neck Cancer, Gastrointestinal Cancer
Interventions
Proactive Psychiatry Consultation (PPC), Enhanced Usual Care (EUC)
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Oct 18, 2026, 8:48 AM EDT
Completed Not applicable Interventional Results available

Cognitive Fitness for Depression in Older Adults

NCT04790630
View directory record Official record
Conditions
Depression Mild, Depressive Disorder, Major, Mild Cognitive Impairment
Interventions
Computerized Cognitive Remediation of Executive Functioning (CCR-EF), Active Control
Other
Lead sponsor
UConn Health
Other
Eligibility
60 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 18, 2026, 8:48 AM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of Vilazodone in Major Depressive Disorder

NCT01473381
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Vilazodone, Placebo to citalopram, Placebo to vilazodone, Citalopram
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
54
States / cities
Birmingham, Alabama • Dothan, Alabama • Scottsdale, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2014 · Synced Oct 18, 2026, 8:48 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder

NCT00854100
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Antidepressant + placebo, Antidepressant + cariprazine (0.1-0.3 mg/day), Antidepressant + cariprazine (1-2 mg/d)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
41
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Arcadia, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 18, 2026, 8:48 AM EDT
Completed Phase 2 Interventional

Trigeminal Nerve Stimulation for Depression: Dose Finding

NCT01343563
View directory record Official record
Conditions
Depression
Interventions
Trigeminal Nerve Stimulation
Procedure
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Oct 18, 2026, 8:48 AM EDT
Completed Not applicable Interventional

Assessment of Cognitive Functioning Before and After Treatment With Duloxetine

NCT00933439
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Duloxetine
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2013 · Synced Oct 18, 2026, 8:48 AM EDT
Completed Not applicable Interventional Results available

Ketamine Infusion for Treatment-resistant Major Depressive Disorder

NCT01582945
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ketamine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Oct 18, 2026, 8:48 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Cholinergic Modulation of Condition and Emotion in Mood Disorders: Functional Neuroimaging Studies

NCT00055575
View directory record Official record
Conditions
Mood Disorders, Healthy, Unipolar Depression, Bipolar Depression
Interventions
Scopolamine Nasal Spray
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 55 Years
Enrollment
197 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 22, 2021 · Synced Oct 18, 2026, 8:48 AM EDT